Evercore downgrades Twist Bioscience to In-Line, target $102

0 min read | Published on 24 Jun 2026, 09:30 PM |Updated on 06 Jul 2026, 08:28 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Evercore ISI Group analyst Vijay Kumar downgraded Twist Bioscience to In-Line from Outperform, raising the price target to $102 from $66. This contrasts with a recent Guggenheim report that maintained a Buy rating with a $107 target.

*this image is generated using AI for illustrative purposes only.

Evercore ISI Group analyst Vijay Kumar has downgraded Twist Bioscience (NASDAQ: TWST) to In-Line from Outperform while raising the price target to $102 from the previous $66. The revised rating and target reflect a shift in the firm's perspective on the stock's potential performance relative to the broader market.

Rating and Target Details

The adjustment follows a review of the company's position within the synthetic DNA market. While the price target increase suggests a higher valuation expectation, the downgrade to In-Line indicates a more cautious stance on the stock's ability to outperform peers.

Firm	Rating	Previous Target	New Target
Evercore ISI Group	In-Line	$66	$102
Guggenheim	Buy	$60	$107

Twist Bioscience specializes in synthetic DNA and serves various sectors including healthcare and industrial chemicals. The conflicting analyst views highlight differing opinions on the company's growth trajectory and market valuation.

What specific market factors could drive Twist Bioscience's stock to meet the new $102 price target despite the downgrade?

How might the divergence between Evercore's and Guggenheim's ratings influence investor sentiment in the short term?

What upcoming catalysts or product launches could shift analyst sentiment back to an Outperform rating?

Twist Bioscience files prospectus for mixed shelf offering

0 min read | Published on 19 Jun 2026, 02:12 AM |Updated on 19 Jun 2026, 02:12 AM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Key Highlights

Twist Bioscience has filed a prospectus for a mixed shelf offering with the SEC. The filing does not disclose the specific terms or the aggregate amount of securities to be offered. This registration allows the company to issue various types of securities over time.

*this image is generated using AI for illustrative purposes only.

Twist Bioscience has filed a prospectus for a mixed shelf offering, though the specific terms of the securities to be sold remain undisclosed. The company submitted the filing to the United States Securities and Exchange Commission (SEC) to register the offering. This move provides the company with the flexibility to offer various types of securities in the future.

Filing Details

The prospectus was filed via the SEC's EDGAR system. A mixed shelf offering allows a company to register different classes of securities, such as common stock, preferred stock, debt securities, or warrants, which it can issue over time. By filing now, Twist Bioscience positions itself to raise capital quickly when market conditions are favorable without needing to file separate paperwork for each transaction.

The document does not specify the aggregate amount of securities being registered. Consequently, the financial impact of the offering cannot be determined from the current filing. Investors will need to wait for a subsequent prospectus supplement to understand the pricing, size, and specific use of proceeds for any issuance under this shelf registration.

What strategic initiatives or expansion plans might Twist Bioscience be preparing to fund with this capital?

How will current market conditions influence the timing and pricing of the securities issued under this shelf offering?

Could this move signal a shift in Twist Bioscience's capital structure, such as increasing debt or equity financing?